FOSTER CITY, Calif.–Navigenics, a leading personal genomics testing company, announced today that Michael J. Critelli has been appointed to its board of directors.

Upon his retirement in February 2009, Mr. Critelli completed a nearly 30-year career at Pitney Bowes Inc. where he served as CEO for 11 years and Chairman for 12 years. Under his leadership, the company was transformed into an industry leader with an expertise in secure business communications, and drove toward the globalization of its markets, products, business processes, and human resources.

Mr. Critelli’s leadership also extends to health care and healthy communities, diversity, and corporate social responsibility. At Pitney Bowes he took a unique approach to tackling diseases such as obesity by implementing special prevention and wellness programs resulting not only in cost savings and improved health and morale for employees, but also in benefits to the company by reducing costs from disability, workers compensation, and absenteeism and improved productivity. In addition to his promotion of corporate wellness initiatives, Mr. Critelli has also been a leader of national and global efforts to advance leading-edge onsite health care delivery and encourage health care quality improvement and cost containment strategies.

“I am very passionate about improving health care and am excited to be a part of Navigenics’ mission to improve health across the population,” says Mr. Critelli. “New tools and technologies like genetic testing can help us personalize our health in ways we never could before, and have the potential to transform today’s growing corporate wellness programs with truly customized prevention strategies. By making these tools more accessible and providing incentives, we can empower individuals to be more proactive in managing their own health.”

“We are thrilled to welcome Michael to our board,” said Jack Lord, president and CEO of Navigenics. “His unique leadership and industry experience – from the reinvention of Pitney Bowes to his innovation in employer-based health care – will bring an important perspective to our team and will help us broaden the business as we continue to expand the reach and impact of personalized genomics.”

Mr. Critelli currently serves as the Chairman of the Board for the Dossia Foundation, an organization funding an independent non-profit institute to develop a web-based framework for secure, private and portable patient-controlled health records, and the Dossia Service Corporation, a subsidiary of the Foundation formed to manage the delivery of Dossia services. He also serves on the Board of Directors for both Wyeth and the Eaton Corporation, as well as the Partnership for Prevention and the RAND Health Advisors boards, the Institute of Medicine’s Roundtable for Evidence-Based Medicine, the Dean’s Advisory Board for the Boston University Medical School, and the Boston University Alzheimer’s Disease Center’s Advisory Board.

ABOUT NAVIGENICS

Navigenics, Inc. is a privately held company based in Foster City, Calif. The company was founded by David Agus, M.D. and Dietrich Stephan, Ph.D., with the goal of improving health outcomes in individuals across the population. Navigenics educates and empowers individuals and their physicians with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics’ lead investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr Davidow Ventures. More information can be found at www.navigenics.com.